Mid
A
AGENAI Stock Diagnostic Report
Agenus reports response rate in colon cancer trial
아제누스가 국소 진행성 대장암 2상에서 실험적 면역항암제 병용요법 후 수술 시 잔존암이 검출되지 않은 환자 비율이 72%였다고 보고하며 긍정적입니다.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$6.33Reference entry price at analysis time
01
FUNDAMENTALS
Financial & Fundamental Analysis
Phase 2 clinical trial results demonstrated a tumor cell disappearance response in 72% of patients; however, specific financial metrics and commercialization schedules were not specified in the document, limiting short-term performance contribution.
02
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The 72% clinical phase 2 response rate for the combination therapy of immune checkpoint inhibitors in locally advanced colorectal cancer, presented by the European Society of Urology (ESMO) and other European societies, acts as positive momentum for future pipeline valuation.